These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33184423)

  • 1. Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction.
    Núñez LM; Romero E; Julià-Sapé M; Ledesma-Carbayo MJ; Santos A; Arús C; Candiota AP; Vellido A
    Sci Rep; 2020 Nov; 10(1):19699. PubMed ID: 33184423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.
    Wu S; Calero-Pérez P; Villamañan L; Arias-Ramos N; Pumarola M; Ortega-Martorell S; Julià-Sapé M; Arús C; Candiota AP
    NMR Biomed; 2020 Apr; 33(4):e4229. PubMed ID: 31926117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
    Delgado-Goñi T; Ortega-Martorell S; Ciezka M; Olier I; Candiota AP; Julià-Sapé M; Fernández F; Pumarola M; Lisboa PJ; Arús C
    NMR Biomed; 2016 Jun; 29(6):732-43. PubMed ID: 27061401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
    Delgado-Goñi T; Julià-Sapé M; Candiota AP; Pumarola M; Arús C
    NMR Biomed; 2014 Nov; 27(11):1333-45. PubMed ID: 25208348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
    Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
    NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
    Wu S; Calero-Pérez P; Arús C; Candiota AP
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma.
    Hirono S; Hasegawa Y; Sakaida T; Uchino Y; Hatano K; Iuchi T
    Sci Rep; 2019 Nov; 9(1):17794. PubMed ID: 31780768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [
    Provost C; Rozenblum-Beddok L; Nataf V; Merabtene F; Prignon A; Talbot JN
    Mol Imaging Biol; 2019 Apr; 21(2):297-305. PubMed ID: 29948641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
    Johannessen TC; Hasan-Olive MM; Zhu H; Denisova O; Grudic A; Latif MA; Saed H; Varughese JK; Røsland GV; Yang N; Sundstrøm T; Nordal A; Tronstad KJ; Wang J; Lund-Johansen M; Simonsen A; Janji B; Westermarck J; Bjerkvig R; Prestegarden L
    Int J Cancer; 2019 Apr; 144(7):1735-1745. PubMed ID: 30289977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
    Petrova L; Korfiatis P; Petr O; LaChance DH; Parney I; Buckner JC; Erickson BJ
    J Neurol Sci; 2019 Oct; 405():116433. PubMed ID: 31476621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex as a biological variable in response to temozolomide.
    Russell L; Bolyard C; Banasavadi-Siddegowda Y; Weiss A; Zhang J; Shakya R; Powell K; Kaur B
    Neuro Oncol; 2017 Jun; 19(6):873-874. PubMed ID: 28379437
    [No Abstract]   [Full Text] [Related]  

  • 12. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
    van Leyen K; Roelcke U; Gruber P; Remonda L; Berberat J
    J Neuroimaging; 2019 Sep; 29(5):645-649. PubMed ID: 31112344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.
    Proske J; Walter L; Bumes E; Hutterer M; Vollmann-Zwerenz A; Eyüpoglu IY; Savaskan NE; Seliger C; Hau P; Uhl M
    Anticancer Res; 2016 Mar; 36(3):899-905. PubMed ID: 26976976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
    Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
    Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma.
    Renziehausen A; Tsiailanis AD; Perryman R; Stylos EK; Chatzigiannis C; O'Neill K; Crook T; Tzakos AG; Syed N
    Mol Cancer Ther; 2019 Sep; 18(9):1497-1505. PubMed ID: 31213505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
    Nickel AC; Wan XY; Saban DV; Weng YL; Zhang S; Keyvani K; Sure U; Zhu Y
    J Neurooncol; 2019 Jan; 141(1):31-41. PubMed ID: 30392087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma.
    Massey SC; White H; Whitmire P; Doyle T; Johnston SK; Singleton KW; Jackson PR; Hawkins-Daarud A; Bendok BR; Porter AB; Vora S; Sarkaria JN; Hu LS; Mrugala MM; Swanson KR
    PLoS One; 2020; 15(3):e0230492. PubMed ID: 32218600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
    López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
    Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.